Table 1.
Demographic data of patients and healthy control subjects. For statistical analysis, two-tailed, unpaired t-test or Fisher’s exact test was used. Abbreviations: EDSS: Expanded Disability Status Scale; DMT: disease-modifying treatment; PPMS: primary progressive MS; RRMS: relapsing remitting MS; SPMS: secondary progressive MS; s: strongest leg; T25FW: Timed-25 foot walk; w- weakest leg; 6MWT: 6-minute walk test.
| patients | healthy controls | P-values | |
|---|---|---|---|
| number of participants | 37 | 20 | |
| age [y] | 48.6 ± 10.3 | 48.8 ± 10.1 | 0.9286 |
| female [%] | 24/37 | 12/20 | 0.7780 |
| height [cm] | 170.4 ± 9.9 | 170.9 ± 7.0 | 0.4642 |
| weight [kg] | 68.5 ± 17.1 | 71.7 ± 11.5 | 0.8600 |
| disease type: RRMS/PPMS/SPMS | 22/2/13 | ||
| disease duration [y] | 10.7 ± 6.9 | ||
| T25FW [s] | 6.2 ± 2.7 | 3.6 ± 0.4 | <0.0001 |
| 6mWT [m] | 397.0 ± 116.0 | 709.9 ± 74.7 | <0.0001 |
| EDSS [pts] | 4.5 ± 1.0 | ||
| manual muscle testing: | |||
| hip flexion (w/s) | 4.39/4.69 | 5/5 | |
| knee flexion (w/s) | 4.39/4.87 | 5/5 | |
| knee extension (w/s) | 4.74/4.93 | 5/5 | |
| ankle extension (w/s) | 4.47/4.87 | 5/5 | |
|
DMT of multiple sclerosis
(number of patients) | |||
| interferon | 6 | ||
| fingolimod | 4 | ||
| natalizumab | 12 | ||
| no treatment | 15 | ||